An Open Label, Two Stage, Phase II Study to Evaluate the Efficacy and Tolerability of ZD6474 in Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Carcinoma

Trial Profile

An Open Label, Two Stage, Phase II Study to Evaluate the Efficacy and Tolerability of ZD6474 in Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Carcinoma

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Jul 2017

At a glance

  • Drugs Vandetanib (Primary)
  • Indications Thyroid cancer
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 19 Jun 2017 Status changed from active, no longer recruiting to completed.
    • 24 Aug 2016 Planned End Date changed from 1 Jun 2016 to 1 Dec 2019.
    • 04 May 2016 Planned End Date changed from 1 Mar 2016 to 1 Jun 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top